HRT Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

HRT Financial’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.8M	Buy	613,229 +111,550	+22%	+$2.51M	0.03%	522
2025 Q4	$11.5M	Buy	+501,679	New	+$16.5M	0.04%	404
2025 Q3	–	Sell	-79,824	Closed	-$2.9M	–	3517
2025 Q2	$2.9M	Buy	79,824 +45,389	+132%	+$1.64M	0.01%	764
2025 Q1	$1.25M	Buy	34,435 +5,935	+21%	+$247K	0.01%	1031
2024 Q4	$1.2M	Buy	28,500 +4,825	+20%	+$239K	0.01%	981
2024 Q3	$1.31M	Buy	+23,675	New	+$1.21M	0.01%	1087
2024 Q2	–	Sell	-7,869	Closed	-$367K	–	2938
2024 Q1	$367K	Sell	7,869 -10,430	-57%	-$492K	﹤0.01%	1430
2023 Q4	$875K	Buy	+18,299	New	+$709K	0.01%	1058
2023 Q3	–	Sell	-59,300	Closed	-$2.73M	–	2963
2023 Q2	$2.73M	Buy	59,300 +48,838	+467%	+$2.27M	0.03%	480
2023 Q1	$419K	Sell	10,462 -20,022	-66%	-$859K	0.01%	1505
2022 Q4	$1.41M	Buy	+30,484	New	+$1.2M	0.02%	750
2021 Q3	–	Sell	-156,948	Closed	-$15M	–	3676
2021 Q2	$15M	Buy	+156,948	New	+$16.4M	0.14%	133

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

HRT Financial's RARE Position: Q1 2026 in Review

HRT Financial increased its Ultragenyx Pharmaceutical (RARE) stake by 22% in Q1 2026, buying an estimated $2.51M and bringing the position to 613,229 shares worth $12.8M. The position accounts for 0.03% of the portfolio, ranked #522.

HRT Financial first reported a position in RARE in Q2 2021 and has held it in 12 quarters since. The position peaked at $15M in Q2 2021. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

HRT Financial held 613,229 shares of Ultragenyx Pharmaceutical worth $12.8M as of Q1 2026.
HRT Financial bought 111,550 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $2.51M.
Ultragenyx Pharmaceutical made up 0.03% of HRT Financial's portfolio in Q1 2026, its #522 holding.
HRT Financial first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and has held it in 12 quarters since.
HRT Financial's Ultragenyx Pharmaceutical position peaked at $15M in Q2 2021.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.